Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

AbCellera falls as FDA says co's bebtelovimab may not neutralize new COVID subvariants

** AbCellera Biologics' shares  ABCL.O  erase early gains,
now down 2.4% at $11.82 in afternoon trade
    ** FDA says ABCL-discovered bebtelovimab is not expected to
neutralize Omicron subvariants BQ.1 and BQ.1.1
    ** The two Omicron subvariants now account for about 35% of
COVID cases in the U.S.
    ** Bebtelovimab is the second COVID-19 antibody discovered
by ABCL and was licensed to Eli Lilly and Co  LLY.N  for
development, manufacturing and commercialization
    ** ABCL got $33.2 mln in royalty revenue in Q2, driven by
bebtelovimab 
    ** All six brokerages covering ABCL rate the stock "buy" or
higher; their median PT is $32
    ** Including session's loss, stock down 16% YTD
 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))

Recent news on AbCellera Biologics

See all news